Drugs / Plasmalyte A
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT03043131 | Feb → Sep 2017 | — | Post Graduate Institute of Medical Education and Research, Chandigarh | Unknown | No outcome recorded |
| Phase 42 trials · 1 met primary | ||||||
| Phase 4 | NCT03115060 | Apr 2015 → Apr 2018 | disorder of acid-base balance | Post Graduate Institute of Medical Education and Research, Chandigarh | Unknown | No outcome recorded |
| Phase 4 | NCT01234883 | Jun 2011 → Feb 2013 | gastroenteritis | Baxter Healthcare Corporation | Terminated | Met primary Stop: Enrollment |
| Phase not applicable1 trial | ||||||
| — | NCT03818126 | Jul 2016 → Jun 2018 | aortic valve disorder, ischemic disease | Pawel Buszman | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Plasmalyte A | “Compare the efficacy and safety of Plasma-Lyte A (PLA) versus 0.9 % sodium chloride (NaCl) intravenous (IV) fluid replacement in children with moderate to severe dehydration...” PMID 27480410 ↗ Aug 20163“The del Nido components are: Plasma-Lyte A (1000ml), Mannitol 20% (16.3ml), MgSO4 50% (4ml) , NaHCO3 8.4% (13ml) , KCl 2mEq/mL (13ml), Lidocaine 1% (13ml).” NCT03818126 ↗ |
| Known as | PLA | “Plasma-Lyte A (PLA)” PMID 27480410 ↗ Aug 2016 |
| Known as | Plasmalyte | “Plasmalyte is another fluid which can be used and probably will lead to better metabolic profile in these group of patients” NCT03115060 ↗ |
| Route | Intravenous | “Plasma Lyte-A injection, pH 7.4, is a sterile, nonpyrogenic isotonic solution, for intravenous administration.” NCT03043131 ↗ |